Myasthenia Gravis
Welcome,         Profile    Billing    Logout  
 64 Companies   21 Products   21 Products   23 Mechanisms of Action   207 Trials   10745 News 


«12...125126127128129130131132133134135136137»
  • ||||||||||  NN1213 / Novo Nordisk
    Enrollment open, Trial completion date, Trial primary completion date:  Tissue Repository for Studies of Myasthenia Gravis (clinicaltrials.gov) -  Aug 23, 2018   
    P=N/A,  N=300, Enrolling by invitation, 
    Active, not recruiting --> Completed Active, not recruiting --> Enrolling by invitation | Trial completion date: Aug 2018 --> Aug 2019 | Trial primary completion date: Aug 2017 --> Aug 2019
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Trial completion date, Trial primary completion date:  MGEX: Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis (clinicaltrials.gov) -  Aug 13, 2018   
    P=N/A,  N=45, Completed, 
    Active, not recruiting --> Enrolling by invitation | Trial completion date: Aug 2018 --> Aug 2019 | Trial primary completion date: Aug 2017 --> Aug 2019 Recruiting --> Completed | Trial completion date: Jul 2019 --> Apr 2018 | Trial primary completion date: Oct 2018 --> Jan 2018
  • ||||||||||  Zilbrysq (zilucoplan) / UCB
    Enrollment closed:  Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis (clinicaltrials.gov) -  Aug 10, 2018   
    P2,  N=44, Active, not recruiting, 
    Recruiting --> Completed | Trial completion date: Jul 2019 --> Apr 2018 | Trial primary completion date: Oct 2018 --> Jan 2018 Recruiting --> Active, not recruiting
  • ||||||||||  NN1213 / Novo Nordisk
    Enrollment closed, Trial completion date, Trial primary completion date:  Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis (clinicaltrials.gov) -  Jul 16, 2018   
    P2,  N=60, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial completion date: Aug 2018 --> Mar 2019 | Trial primary completion date: Jul 2018 --> Mar 2019
  • ||||||||||  Review, Journal, Adverse events, Checkpoint inhibition:  CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects. (Pubmed Central) -  Jul 8, 2018   
    Checkpoint inhibitors enhance the immune system by releasing inhibition on T cells, with risk of autoimmune-like side effects. Ophthalmologists should include immune-related adverse events in their differential when examining cancer patients with new ocular symptoms.
  • ||||||||||  mycophenolate mofetil / Generic mfg., azathioprine / Generic mfg.
    Enrollment open, HEOR:  PROMISE-MG: Disease-Modifying Treatments for Myasthenia Gravis (clinicaltrials.gov) -  Jun 6, 2018   
    P=N/A,  N=220, Recruiting, 
    Ophthalmologists should include immune-related adverse events in their differential when examining cancer patients with new ocular symptoms. Not yet recruiting --> Recruiting
  • ||||||||||  Myasterix (CV-MG01) / CuraVac
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date:  A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis (clinicaltrials.gov) -  May 31, 2018   
    P2/3,  N=0, Withdrawn, 
    Not yet recruiting --> Recruiting N=66 --> 0 | Trial completion date: Dec 2018 --> Dec 2019 | Not yet recruiting --> Withdrawn | Trial primary completion date: Oct 2018 --> Oct 2019
  • ||||||||||  Rituxan (rituximab) / Roche
    Trial completion date, Trial primary completion date:  A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis (clinicaltrials.gov) -  Apr 4, 2018   
    P3,  N=60, Recruiting, 
    However, these differences seem to have little impact on outcomes. Trial completion date: Dec 2018 --> Jun 2020 | Trial primary completion date: Aug 2018 --> Sep 2019
  • ||||||||||  NN1213 / Novo Nordisk
    Phase classification:  Training for Diagnosing Neurological Disorders (clinicaltrials.gov) -  Mar 30, 2018   
    P,  N=400, Recruiting, 
    Trial completion date: Dec 2018 --> Jun 2020 | Trial primary completion date: Aug 2018 --> Sep 2019 Phase classification: P=N/A --> P
  • ||||||||||  Firdapse (amifampridine) / BioMarin, Catalyst Pharma, Dydo Pharma
    Enrollment open:  Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG (clinicaltrials.gov) -  Mar 9, 2018   
    P3,  N=60, Recruiting, 
    Phase classification: P=N/A --> P Not yet recruiting --> Recruiting
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
    Trial completion date, Trial primary completion date:  BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis (clinicaltrials.gov) -  Mar 3, 2018   
    P2,  N=52, Active, not recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Dec 2017 --> May 2018 | Trial primary completion date: May 2017 --> Jul 2017
  • ||||||||||  Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
    Enrollment closed, Trial initiation date, Trial primary completion date:  Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis (clinicaltrials.gov) -  Mar 2, 2018   
    P2,  N=25, Active, not recruiting, 
    Trial completion date: Dec 2017 --> May 2018 | Trial primary completion date: May 2017 --> Jul 2017 Recruiting --> Active, not recruiting | Initiation date: Jan 2015 --> May 2015 | Trial primary completion date: Dec 2018 --> Nov 2017
  • ||||||||||  Firdapse (amifampridine) / BioMarin, Catalyst Pharma, Dydo Pharma
    Trial completion date, Trial primary completion date:  Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes (clinicaltrials.gov) -  Feb 23, 2018   
    P3,  N=20, Recruiting, 
    Recruiting --> Active, not recruiting | Initiation date: Jan 2015 --> May 2015 | Trial primary completion date: Dec 2018 --> Nov 2017 Trial primary completion date: Jun 2018 --> Nov 2018 | Trial completion date: Jul 2018 --> Dec 2018
  • ||||||||||  Trial completion date, Trial primary completion date:  Myasthenia Gravis and Psyche (clinicaltrials.gov) -  Feb 5, 2018   
    P=N/A,  N=4300, Recruiting, 
    Further insights into the autoimmune mechanism of PM will hopefully contribute to the prevention and treatment of this phenomenon. Trial primary completion date: Dec 2017 --> Dec 2018 | Trial completion date: Dec 2017 --> Dec 2018
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Trial primary completion date:  Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases (clinicaltrials.gov) -  Jan 18, 2018   
    P2,  N=40, Recruiting, 
    Trial primary completion date: Sep 2017 --> Sep 2019 Trial primary completion date: Dec 2017 --> Dec 2018
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Journal:  Myasthenia Gravis After Nivolumab Therapy for Squamous Cell Carcinoma of the Bladder. (Pubmed Central) -  Jan 5, 2018   
    This is the first case, to our knowledge, reported in association with bladder cancer. The precise diagnosis of MG has important implications on management, as treatment with steroids can transiently worsen myasthenia in nearly 50% of cases.
  • ||||||||||  Firdapse (amifampridine) / BioMarin, Catalyst Pharma, Dydo Pharma
    Trial primary completion date:  Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes (clinicaltrials.gov) -  Jan 5, 2018   
    P3,  N=20, Recruiting, 
    The precise diagnosis of MG has important implications on management, as treatment with steroids can transiently worsen myasthenia in nearly 50% of cases. Trial primary completion date: Oct 2017 --> Jun 2018
  • ||||||||||  Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
    Trial primary completion date:  Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis (clinicaltrials.gov) -  Nov 1, 2017   
    P2,  N=25, Recruiting, 
    Recruiting --> Active, not recruiting Trial primary completion date: May 2017 --> Dec 2018
  • ||||||||||  prednisone / Generic mfg., azathioprine / Generic mfg.
    Trial completion, Trial primary completion date:  MYACOR: Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis (clinicaltrials.gov) -  Sep 27, 2017   
    P4,  N=118, Completed, 
    N=10000 --> 20000 Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Jul 2017
  • ||||||||||  Biomarker, Enrollment open, Enrollment change, Trial primary completion date:  Biomarkers in Neural Disorders (clinicaltrials.gov) -  Sep 11, 2017   
    P=N/A,  N=440, Recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Jul 2017 Terminated --> Recruiting | N=35 --> 440 | Trial primary completion date: May 2017 --> Jun 2022
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Journal:  Is MuSK myasthenia gravis linked to IgG4-related disease? (Pubmed Central) -  Aug 19, 2017   
    She was started on rituximab with clinical improvement and ability to taper immunomodulatory agents for the first time. Our case raises number of questions regarding a potential link between MuSK MG and IgG4-RD which may shed further light on the pathophysiology and management of these diseases.
  • ||||||||||  Trial completion:  Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome (clinicaltrials.gov) -  Jul 11, 2017   
    P2,  N=32, Completed, 
    Further insights into the autoimmune mechanism of PM will hopefully contribute to the prevention and treatment of this phenomenon. Active, not recruiting --> Completed
  • ||||||||||  New trial:  Myasthenia Gravis and Psyche (clinicaltrials.gov) -  Jul 2, 2017   
    P=N/A,  N=4300, Recruiting,